Bio-Techne (TECH) Akcija Цена

Bio-Techne Цена

NASDAQ·ZATVORENO
72,47
​
Tržište je zatvoreno

Prihod je rastao 9,3 % godišnje u poslednjih 19 godina na 1,22 Млрд USD. Zarada po akciji rasla je 4,1 % godišnje u poslednjih 19 godina. neto marža kompanije Bio-Techne sada iznosi 15,0 %, pala sa 24,6 % pre nekoliko godina. Bio-Techne trenutno nudi dividendni prinos od oko 0,44 %. Odnos isplate je oko 40 % dobiti. Dividenda je rasla 9,5 % godišnje u poslednjih 18 godina. Medijana analitičke ciljane cene je 73,00 USD, odnosno iznad trenutnu cenu za 0,7 %. Od 22 analitičara 7 preporučuje kupovinu — ukupni konsenzus je Drži.

Cena akcije Bio-Techne

Pristupite ovim podacima preko Eulerpool API-ja

Bio-Techne poslovni model i analiza akcije

Bio-Techne Corp je globalna kompanija specijalizovana za istraživanje i razvoj inovativnih proizvoda i rešenja iz oblasti bioscience. Kompanija je osnovana 1976. godine u Minneapolisu i ranije je bila poznata kao Techne Corporation. Od tada je, kroz brojna preuzimanja i spajanja, postala međunarodno priznata kompanija. Štab kompanije nalazi se u Minneapolisu, u američkoj državi Minesota. Poslovna filozofija Bio-Techne Corp-a je da pomogne bioscientističkim istraživačima i kliničarima širom sveta da svoj rad obavljuju efikasnije, efikasnije i brže. Kompanija usko sarađuje sa svojim kupcima kako bi im pružila odgovarajuće proizvode i usluge, čime razvija inovativna rešenja za izazove u oblasti bioscience. Bio-Techne Corp ima različite poslovne segmente, uključujući proteinske platforme, dijagnostiku, genetsku analizu, kliničke kontrole, proizvode za kulturu ćelija i istraživačke reagense. Svaki poslovni segment nudi širok spektar proizvoda i usluga koji podržavaju istraživače i kliničare u njihovom radu. Ključni poslovni segment Bio-Techne Corp-a je proteinska platforma, koja nudi sveobuhvatan raspon proteina, antitela i odgovarajućih detekcijskih agenasa. Kompanija je poznata po visokokvalitetnim proteinima i antitelima, koji doprinose poboljšanju istraživanja bolesti poput raka, dijabetesa, neuroloških i imunoloških poremećaja. Još jedan važan poslovni segment Bio-Techne Corp-a je dijagnostika. Ovde kompanija nudi širok spektar kliničkih dijagnostičkih proizvoda, kao što su testovi za analizu ureje, kreatinina i gustine kostiju. Proizvodi kompanije pomažu kliničarima da donesu precizne dijagnoze i efikasnije leče pacijente. Segment genetske analize nudi proizvode i usluge za sekvenciranje DNK, analizu ekspresije gena i analize celog genoma. Ovi alati omogućavaju istraživačima da bolje razumeju funkcionisanje ljudskog tela istraživanjem osnovnih genetskih promena. Segment kliničkih kontrola nudi ponudu proizvoda i usluga koje poboljšavaju pouzdanost i tačnost dijagnostičkih sistema. Kompanija usko sarađuje sa medicinskim ustanovama kako bi pružila dijagnostička rešenja koja daju brze i tačne rezultate. Segment proizvoda za kulturu ćelija nudi kompletan raspon rešenja za kultivaciju i rast ćelija. Ponuda obuhvata osnovne nutritivne medije i aditive, kao i posude za kulturu i pribor. Proizvodi kompanije omogućavaju istraživačima da kultivišu ćelije u kontrolisanim uslovima i pod preciznim parametrima. Poslednji segment Bio-Techne Corp-a uključuje istraživačke reagense. Ovde kompanija nudi širok spektar agenasa koji se koriste za analizu i istraživanje funkcije proteina, antitela i ćelija. Proizvodi zadovoljavaju potrebe istraživača u savremenoj bioscience. Ukratko, Bio-Techne Corp je kompanija specijalizovana za razvoj inovativnih rešenja u oblasti bioscience, unapređujući nauku i medicinu. Svojim proizvodima i uslugama koje nudi u različitim sektorima, kompanija uspešno pomaže istraživačima i kliničarima da svoj rad obavljaju brže, efikasnije i isplativije.

Često postavljana pitanja o akciji Bio-Techne

Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.

Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.

Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.

Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.

Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.

Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.

Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 65,78 USD za akciju Bio-Techne (medijana: 73,00 USD), što znači -9,2 % u odnosu na poslednju cenu. Konsenzus se zasniva na 22 ocena.

22 analitičara trenutno ocenjuje akciju Bio-Techne: 7 preporučuje kupovinu, 15 držanje i 0 prodaju.

Po trenutnom kursu akcija Bio-Techne kotira 64,67 EUR (72,47 USD).

Akcija Bio-Techne (TECH) kotira na 4 berze, uključujući: NASDAQ (TECH), Frankfurt (TE1.F), München (TE1.MU), Düsseldorf (TE1.DU).

Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.

prihod od Bio-Techne je 1,22 Млрд USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

dobit od Bio-Techne je 181,86 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Bio-Techne je trenutno 62,57. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Bio-Techne.

Odnos cene i prihoda (KUV) za Bio-Techne je trenutno 9,36. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Bio-Techne.

Eulpool score kvaliteta za Bio-Techne je 4/10.

ISIN za Bio-Techne je US09073M1045. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Bio-Techne je A12ENG. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Bio-Techne je TECH. Simbol tikera se koristi za trgovinu akcijama Bio-Techne na berzanskom tržištu.

Фер вредностTerminal
72,47 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Алати и услуге науке о животу
Број акција
Запослени
Приход по запосленом
391.948,06 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт bio-techne.com
Валута
USD
Јавна понуда
9. феб 1989.
ISIN
US09073M1045
CUSIP
09073M104
SEDOL
BSHZ3Q0
Тржишна капитализација
Опсег од 52 недеље
AAQS
4 / 10
PEG
8,86
P/E однос
P/Ee 2027
35,66
P/Ee 2028
30,81
P/Ee 2029
29,82
P/Ee 2030
27,14
P/Ee 2031
—
P/S
P/Se
8,97
EV/EBIT
45,95
P/B однос
5,44
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
8,54 %
Дивиденда
Прinos од дивиденде
0,44 %
Процењени принос од дивиденде
0,44 %
Стопа исплате
40,49 %
Раст дивиденде Ø5Y
-0,20 %
Дивиденде по години
4
Дивиденда исплаћена од
18 година
Дивиденда није смањена од
1 година
Дивиденда повећана од
0 година
Порез на дивиденде
30,00 %
Zadnje ažurirano 10. окт 2026. 14:49

Bio-Techne Тикер

DISELORF · TE1.DUFRANKFURT · TE1.FMINHEN · TE1.MUNASDAQ · TECH

Bio-Techne FIGI

TECH:US · BBG000C15114TECH:UA · BBG000C15196TECH:UC · BBG000C151R6TECH:UN · BBG000C152W8TECH:UP · BBG000C153L8TECH:UB · BBG000C154P2TECH:UM · BBG000C155S6TECH:UX · BBG000C15668TECH:UD · BBG000C15864TECH:UW · BBG000C159P1TECH:UF · BBG000C15B58TECH:VY · BBG000C15BZ5

Sve ključne metrke i detaljne analize Bio-Techne u dubinskoj analizi

Naša analiza akcija za akciju Bio-Techne uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Bio-Techne. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: